What does remission mean for Leukemia and how is it monitored

Understanding Remission in Leukemia

What Remission Means

Remission is the goal of leukemia treatment. According to the NCCN Guidelines for Patients: Acute Myeloid Leukemia, remission means that leukemia cells have disappeared or are no longer detectable in your blood and bone marrow.

Think of it this way: In leukemia, abnormal blast cells (immature white blood cells) build up and crowd out healthy blood cells. When treatment works, these abnormal cells are eliminated or reduced to undetectable levels. That's remission.

Important distinction: Remission is NOT the same as a cure. Remission means the cancer is under control and not actively growing, but it doesn't necessarily mean the leukemia won't return.

---

Types of Remission Response

The NCCN Guidelines describe different levels of treatment response:

Complete Response (CR)

• This is the best outcome from initial treatment
• Leukemia cells are no longer visible in your bone marrow or blood
• Your blood counts return to normal or near-normal levels
• This is what doctors aim for during the initial treatment phase (called "induction")

Minimal Residual Disease (MRD)

• Even after a complete response, tiny numbers of leukemia cells may remain—too few to see under a regular microscope
• When MRD is detected, it's called MRD-positive (MRD+)
• When MRD cannot be detected, it's called MRD-negative (MRD-)
• MRD status helps doctors understand how well treatment is working and guides decisions about additional therapy

---

How Remission Is Monitored

Your care team uses several methods to check if you're in remission and to catch any signs of leukemia returning:

Blood Tests (Complete Blood Count - CBC)

Regular blood tests measure:

• Red blood cells (to check for anemia)
• White blood cells and specific types (to see if abnormal blasts are present)
• Platelets (to check clotting ability)

These tests are done frequently during and after treatment to track your response.

Bone Marrow Tests

According to the NCCN Guidelines, bone marrow aspirate and biopsy samples are examined to:

• Count the percentage of blasts in your bone marrow
• Look for any return of leukemia cells
• Assess overall bone marrow health

Genetic and Molecular Testing

Advanced tests detect leukemia even when cells aren't visible under a microscope:

Flow Cytometry - Uses special dyes and light to identify and count specific leukemia cells, even in very small numbers

PCR (Polymerase Chain Reaction) - This is extremely sensitive and can find 1 abnormal cell among more than 100,000 normal cells. The NCCN Guidelines note this is "important when testing for treatment response or remission."

Next-Generation Sequencing (NGS) - Looks at DNA in detail to find mutations that might indicate remaining leukemia cells

Imaging Tests

In some cases, imaging may be used to check for leukemia outside the bone marrow and blood (in lymph nodes, liver, spleen, or other areas).

---

Monitoring Schedule

The frequency of monitoring depends on:

• Your specific type of leukemia
• How well you're responding to treatment
• Your overall health status
• Your treatment plan

During active treatment, you'll have frequent blood tests and bone marrow biopsies. After achieving remission, monitoring continues but may become less frequent over time.

---

Questions to Ask Your Care Team

Based on the NCCN Guidelines recommendations, consider asking:

1. What type of remission response am I aiming for with my treatment?
2. How will you monitor whether I'm in remission? What tests will I have and how often?
3. What does MRD-positive or MRD-negative mean for my specific situation?
4. How long will I need monitoring after achieving remission?
5. What signs or symptoms should I report that might suggest the leukemia is returning?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Patients: Acute Myeloid Leukemia, 2025; NCCN Guidelines for Patients: Chronic Myeloid Leukemia, 2025